Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma) is a healthcare company. It offers pharmaceutical manufacturing, vaccines, medical devices, medical diagnosis, healthcare services and pharmaceutical distribution and retail. The company also offers COVID-19 vaccines and messenger ribonucleic acid (mRNA) vaccines. Fosun Pharma's pipeline products include small Molecule such as FH1701, FCN-437c, SAF-189, FCN-338, YP01001, FH2001, XS-03, ET-26, SZEY-2108, XH-S003, XH-S002, XH-S004, FCN-016; biologics such as HLX10 Han Si Zhuang, HLX10+HLX04, HLX10+HLX07, HLX07, HLX26 + HLX10 + chemotherapy, HLX53, and others. The company offering products therapeutic areas include on solid tumors, hematologic tumors, self-immunity, central nervous system, and chronic diseases such as hepatopathy, metabolic diseases and nephropathy. Fosun Pharma is headquartered in Shanghai, China.
Headquarters
China
Address
Building A, No. 1289 Yishan Road, Shanghai, 200233
Website
www.fosunpharma.com
Telephone
86 21 33987870
No of Employees
40,603
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600196 (SHA)
Revenue (2025)
$5.8B
1.4%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
21.7%
(2025 vs 2024)
Market Cap*
$9.6B
Net Profit Margin (2025)
XYZ
20.0%
(2025 vs 2024)
* As of and is in US$
Shanghai Fosun Pharmaceutical (Group) Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Vaccines: | Pharmaceutical Distribution and Retail | Otezla |
| COVID-19 | Healthcare Services | Vantil |
| mRNA COVID-19 Vaccine | Artesun-Plus | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, Guilin Pharmaceutical secured approval from the National Medical Products Administration for Foscarnet Sodium Injection to treat patients with cytomegalovirus retinitis with acquired AIDS, acyclovir-resistant herpes simplex virus skin and mucous membrane infections. |
| 2025 | Contracts/Agreements | In April, the company entered into an agreement to acquire a stake in Shanghai Henlius Biotech. |
| 2025 | Contracts/Agreements | In April, the company entered into an agreement with Fakeeh Care Group to enhance healthcare innovation in Saudi Arabia. |
Competitor Comparison
| Key Parameters | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Sinopharm Group Co Ltd | Sino Biopharmaceutical Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | Zhejiang Medicine Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Shanghai | Shanghai | Hong Kong City | Lianyungang | Shaoxing |
| State/Province | Shanghai | Shanghai | - | Jiangsu | Zhejiang |
| No. of Employees | 40,603 | 100,251 | 24,379 | 20,238 | 5,815 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chen Yuqing | Chairman | Executive Board | 2025 | 51 |
| Wen Deyong | Vice Chairman | Executive Board | 2022 | 54 |
| Guan Xiaohui | Co-Chairman | Executive Board | 2022 | 55 |
| Liu Yi | Chief Executive Officer; President | Senior Management | 2025 | 51 |
| Huang Zhi | Chief Financial Officer; Senior Vice President | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer